Phase I Trial Opens: Percepta Supplement vs Placebo in Mild Cognitive Impairment — Digital MoCA Primary Endpoint

References

1. 1.Cerebrum DAO Association. (2024). Percepta for Cognitive Optimization: A 6-Month Randomized Controlled Trial With Neurocognitive, Wearable, and Participant-Reported Outcomes in Adults With Mild Cognitive Impairment. ClinicalTrials.gov. NCT07612449. https://clinicaltrials.gov/study/NCT07612449
2. 2.Langa, K. M., & Levine, D. A. (2014). The diagnosis and management of mild cognitive impairment: a clinical review. JAMA, 312(23), 2551-2561. https://doi.org/10.1001/jama.2014.13806
3. 3.Petersen, R. C., Lopez, O., Armstrong, M. J., Getchius, T. S., Ganguli, M., Gloss, D., ... & Rae-Grant, A. (2018). Practice guideline update summary: Mild cognitive impairment. Neurology, 90(3), 126-135. https://doi.org/10.1212/WNL.0000000000004826
4. 4.Tricco, A. C., Soobiah, C., Berliner, S., Ho, J. M., Ng, C. H., Ashoor, H. M., ... & Straus, S. E. (2013). Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ, 185(16), 1393-1401. https://doi.org/10.1503/cmaj.130451
5. 5.Zhang, Y., Li, P., Wang, L., & Chen, H. (2023). Neuroprotective effects of Uncaria tomentosa alkaloids in neurodegenerative diseases: A systematic review. Phytomedicine, 115, 154821. https://doi.org/10.1016/j.phymed.2023.154821